The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.75
Bid: 39.50
Ask: 40.00
Change: -2.00 (-4.79%)
Spread: 0.50 (1.266%)
Open: 43.50
High: 43.50
Low: 38.75
Prev. Close: 41.75
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum shares slump on widened loss and funding talks

Tue, 12th Mar 2024 15:23

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Shares in the Cambridge, England-based pharmaceutical company were down 24% to 26.51 pence in London on Tuesday afternoon.

Sareum said it will publish its result the six months ended December 31 in the week beginning March 25.

It expects to report an operating loss of GBP2.5 million, widening from GBP1.7 million a year earlier.

The company explained that this reflects "the cost of continued and additional investment into clinical research conducted during the period for the furtherance of its SDC-1801 autoimmune disease programme."

It also updated markets on its equity prepayment facility with RiverFort Global Opportunities PCC Ltd.

Sareum has drawn GBP2.3 million to date from two prepayment deposits and the company currently has an outstanding balance of approximately GBP1.3 million under the facility.

Any remaining balances are not due for repayment until the maturity date in August 2025, by which all balances are expected to be settled through the issuance of placing shares.

Previously it has been announced that the facility included a committed third tranche prepayment deposit of GBP300,000.

However, it noted that "due to downward pressure on the company's share price", Sareum has been unable to draw down the third prepayment under the facility.

The company explained that it is now in discussions to assess alternative funding arrangements and has taken steps to preserve its immediate capital utilisation.

It added that, providing alternative funding is secured, the board remains confident that it is on course to deliver topline Phase 1a results in the second quarter of 2024.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
11 Aug 2020 12:36

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

Read more
24 Jul 2020 13:56

UK TRADING UPDATE SUMMARY: Naked Wines Chair Leaves, Online Sales Grow

UK TRADING UPDATE SUMMARY: Naked Wines Chair Leaves, Online Sales Grow

Read more
3 Jun 2020 18:09

Sareum Raises GBP1 Million For TYK2/JAK1 Research Programmes

Sareum Raises GBP1 Million For TYK2/JAK1 Research Programmes

Read more
3 Jun 2020 10:56

UK WINNERS & LOSERS SUMMARY: M&S Gains, B&M Loses On Jefferies Ratings

UK WINNERS & LOSERS SUMMARY: M&S Gains, B&M Loses On Jefferies Ratings

Read more
2 Jun 2020 17:46

Sareum Looks To Raise Cash For TYK2/JAK1 Research Programmes

Sareum Looks To Raise Cash For TYK2/JAK1 Research Programmes

Read more
26 Mar 2020 11:46

Sareum Loss Narrows; Could Secure GBP900,000 From China License Deal

Sareum Loss Narrows; Could Secure GBP900,000 From China License Deal

Read more
17 Dec 2019 13:20

Sareum Holdings Happy With Progress Despite Mixed Year

Sareum Holdings Happy With Progress Despite Mixed Year

Read more
17 Dec 2019 11:55

Sareum Expects Possible Significant Delay To Sierra Milestone Payments

Sareum Expects Possible Significant Delay To Sierra Milestone Payments

Read more
10 Dec 2019 15:57

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
15 Oct 2019 11:43

Sareum Narrows Annual Loss As Immunotherapy Programmes Progress

Sareum Narrows Annual Loss As Immunotherapy Programmes Progress

Read more
27 Sep 2019 09:20

Sareum's SAR-20351 Inhibitor Reduces Tumour Growth In Various Cancers

Sareum's SAR-20351 Inhibitor Reduces Tumour Growth In Various Cancers

Read more
27 Sep 2019 09:10

Sareum Holdings upbeat ahead of cancer research presentation

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Friday that it will present new preclinical data from its 'SDC-1802 TYK2/JAK1' inhibitor cancer research programme at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) international conference, in late October in Boston, Massachusetts.

Read more
27 Aug 2019 13:24

Sareum Optimistic On Cancer Treatment As Partner Changes Focus

(Alliance News) - Small molecule drug developer Sareum Holdings PLC on Tuesday said investee Sierra Oncology will need to look at new options to progress development of a key drug.Sierra to

Read more
27 Aug 2019 08:35

Sareum Holdings expects broadly flat interim losses

(Sharecast News) - Drug developer Sareum expects interim losses to be broadly flat year-on-year as it continues to focus on the development of multiple treatments for cancer and autoimmune diseases.

Read more
25 Jun 2019 18:33

Sareum Raises GBP513,000 Through Discounted Placing For Pipeline Push

(Alliance News) - Sareum Holdings PLC said Tuesday it raised GBP513,000 through a discounted share placing by Hybridan LLP, whilst also opening the offer to retail investors through drug firm at ,

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.